์ธ์๋ฆฐ
์ธ์๋ฆฐ์ ๋๊ฒ๋ฅดํ์ค์ฌ์ ๋ฒ ํ ์ธํฌ์์ ์์ฑ๋๋ ์ค์ํ ํฉํ์ด๋ ํธ๋ฅด๋ชฌ์ ๋๋ค. ์์ํ์์ ๋น๋จ๋ณ ๋ฐ ๋น๋จ๋ณ์ฑ ์ผํค์ฐ์ฆ(DKA) ์น๋ฃ์ ํต์ฌ์ ๋๋ค. ์ ์ ๋ ์์ฉ ๋ฐํ ๋ฐ ์ง์ ์๊ฐ์ ๋ฐ๋ผ ํฌ๊ฒ ๋ถ๋ฅ๋ฉ๋๋ค: * **์ํจ์ฑ (๋ ๊ทค๋ฌ, ๋ฆฌ์คํ๋ก):** ์ฃผ๋ก ๋ณ์ ํ๊ฒฝ์์ DKA ๋๋ ์ค์ฆ ๊ณ ์นผ๋ฅจํ์ฆ์ ๊ธ์ฑ ์์ ํ์ ์ฌ์ฉ๋ฉ๋๋ค. ๋ ๊ทค๋ฌ ์ธ์๋ฆฐ์ ์ ๋งฅ ํฌ์ฌ๊ฐ ๊ฐ๋ฅํ ์ ์ผํ ์ ์ ์ ๋๋ค. * **์ค๊ฐํ (NPH, ๋ ํ ):** ๋ฐ๋ ค๊ฒฌ์ ์ ์ง ์๋ฒ์ ํํ ์ฌ์ฉ๋ฉ๋๋ค. ๋ผ์ง ์ธ์๋ฆฐ์ ๋ฐ๋ ค๊ฒฌ ์ธ์๋ฆฐ๊ณผ ๊ตฌ์กฐ์ ์ผ๋ก ๋์ผํ์ฌ ํญ์ธ์๋ฆฐ ํญ์ฒด ํ์ฑ ์ํ์ ์ต์ํํฉ๋๋ค. * **์ง์ํ (PZI, ๊ธ๋ผ์ง, ๋ํฐ๋ฏธ์ด):** ๊ฐ๋ณด๋ค ์ธ์๋ฆฐ ๋์ฌ๊ฐ ๋น ๋ฅธ ๊ณ ์์ด์ ์ ์ง ์๋ฒ์ ์์ฃผ ์ฌ์ฉ๋ฉ๋๋ค. > **์์ ์์ :** ๊ณ ์์ด ๋น๋จ๋ณ์ ์ข ์ข ์ฌ๋์ ์ 2ํ ๋น๋จ๋ณ๊ณผ ์ ์ฌํ๋ฉฐ, ์ง์ํ ์ธ์๋ฆฐ(์: ๊ธ๋ผ์ง)์ ์กฐ๊ธฐ ๋ฐ ์ ๊ทน์ ์ธ ์ฌ์ฉ๊ณผ ์ ํ์ํ๋ฌผ ์๋จ์ ๋ณํํ๋ฉด ๊ดํด์ ๋๋ฌํ ์ ์์ต๋๋ค. ๋ฐ๋ ค๊ฒฌ ๋น๋จ๋ณ์ ์ผ๋ฐ์ ์ผ๋ก ์ฌ๋์ ์ 1ํ ๋น๋จ๋ณ๊ณผ ์ ์ฌํ์ฌ ํ์ ์ธ๋ถ ์ธ์๋ฆฐ ํฌ์ฌ๊ฐ ํ์ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : Insulin initiates its action by binding to the **tyrosine kinase insulin receptor** on the cell membrane. **Mechanism Pathway:** Receptor binding โ Autophosphorylation โ Activation of **Insulin Receptor Substrates (IRS)** โ Activation of the **PI3K/Akt pathway** โ Translocation of **GLUT4** transport proteins to the cell surface โ Rapid facilitated diffusion of glucose into skeletal muscle and adipose tissue. **Metabolic Effects:** * **Carbohydrate metabolism:** Promotes cellular glucose uptake and hepatic glycogenesis; inhibits glycogenolysis and gluconeogenesis. * **Lipid metabolism:** Stimulates lipogenesis and potently inhibits lipolysis and ketogenesis (crucial for resolving DKA). * **Protein metabolism:** Increases amino acid uptake and protein synthesis. * **Electrolyte shift:** Drives potassium and magnesium into the intracellular space (utilized therapeutically for life-threatening hyperkalemia).
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Diabetic ketoacidosis (Regular insulin) ยท Same protocol using regular insulin as described for dogs ยท IM, IV, SC ยท Varies ยท Until stabilized
- Diabetic ketoacidosis (Glargine) ยท 2 Units per cat SC and 1 Unit per cat IM (regardless of body weight) initially; repeat the IM dose 4 or more hours later if BG > 250-290 mg/dL; repeat the SC dose every 12 hours. ยท SC and IM ยท Initially, then q12h SC ยท Until stabilized
- Severe hyperkalemia ยท 0.5 to 1 Unit/kg IM regular insulin plus 2 grams dextrose per unit of insulin IV ยท IM ยท Once
- Uncomplicated diabetes mellitus (Glargine, Detemir, or PZI) ยท Blood glucose <360 mg/dL: 0.25 Units/kg of ideal body weight SC every 12 hours; Blood glucose >=360 mg/dL: 0.5 Units/kg of ideal body weight SC every 12 hours ยท SC ยท q12h ยท Lifelong ยท If no monitoring in first week, begin with 1 Unit per cat every 12 hours.
- Uncomplicated diabetes mellitus (ProZinc) ยท 0.2-0.7 Units/kg SC every 12 hours given concurrently with or right after a meal ยท SC ยท q12h ยท Lifelong ยท Goal: glucose nadir between 80 & 150 mg/dL.
- Uncomplicated diabetes mellitus (Vetsulin) ยท 0.5 Units/kg SC once daily ยท SC ยท q24h ยท Lifelong
- Uncomplicated diabetes mellitus (Lente) ยท 1 Unit per cat SC twice daily for cats <4kg & 1.5-2 Units/cat twice daily for cats >4kg. Alternatively: 0.25 Units/kg SC twice daily if BG 216-342 mg/dL; 0.5 Units/kg SC twice daily if BG>360mg/dL. ยท SC ยท q12h ยท Lifelong
- Diabetes mellitus ยท 0.5-1 Unit per ferret SC twice daily. Alternatively: 0.1-0.5 Units/kg IM or SC twice daily to start; adjust to optimal dose. ยท SC, IM ยท q12h ยท Lifelong ยท May require insulin to be diluted.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Episodes of hypoglycemia (absolute contraindication)
- Systemic allergy to pork or pork products (specifically for Vetsulin/porcine lente)
์ด์๋ฐ์
- Hypoglycemia (most common and potentially life-threatening)
- Insulin-induced hyperglycemia ('Somogyi effect' due to counter-regulatory hormone release following hypoglycemia)
- Insulin antagonism or resistance
- Rapid insulin metabolism
- Local hypersensitivity reactions to 'foreign' proteins
- Lipodystrophy at the injection site (if sites are not rotated)
์ฝ๋ฌผ ์ํธ์์ฉ
- Beta-adrenergic blockers (e.g., propranolol) ยท Can have variable effects on glycemic control and can mask the clinical signs associated with hypoglycemia.
- Clonidine, Reserpine ยท Can mask the signs associated with hypoglycemia.
- Digoxin ยท Insulin alters serum potassium levels; concurrent use requires close monitoring for cardiac arrhythmias, especially with concurrent diuretics.
- Alcohol, Anabolic steroids, ACE inhibitors, Aspirin, Disopyramide, Fluoxetine, MAOIs, Somatostatin derivatives, Sulfonamides ยท May potentiate the hypoglycemic activity of insulin.
- Calcium channel blockers, Corticosteroids, Danazol, Diuretics, Isoniazid, Niacin, Phenothiazines, Thyroid hormones ยท May decrease the hypoglycemic activity of insulin (cause insulin resistance).
๋ชจ๋ํฐ๋ง
- Blood glucose (serial curves or continuous monitoring)
- Patient weight
- Appetite and water intake
- Urine output
- Blood or urine ketones (if DKA suspected)
- Fructosamine (goal <450 micromol/L) or glycosylated hemoglobin
๊ณผ์ฉ๋
Overdosage of insulin leads to **hypoglycemia**, which can be rapidly fatal or cause permanent brain damage if untreated. **Clinical Signs:** * Weakness, lethargy, ataxia * Shaking, muscle fasciculations * Head tilting, bizarre behavior, blindness * Restlessness, extreme hunger * Seizures and coma **Treatment:** * **Mild:** Offer the animal its usual food. * **Severe (e.g., seizures):** Rub oral dextrose solutions (e.g., **Karoยฎ syrup**) on the oral mucosa (do not pour down the throat to avoid aspiration). * **Veterinary Intervention:** Intravenous injections of 50% dextrose solutions (small amounts, slowly administeredโusually 2-15 mL). * **Monitoring:** Once alleviated (usually within 1-2 minutes), monitor closely with serial blood glucose levels to prevent recurrence (especially with long-acting insulins) and adjust future doses.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.